← TrendWatcher
Google Trends
6/10

CompoundCompanion

A consumer health app that translates peptide research into plain language, logs your protocol, flags risky drug interactions, and generates a doctor-shareable summary before your next appointment.

Target user

biohackers and health-conscious adults researching or already using off-label peptide therapy

Features
  • Protocol logger that records dose, schedule, source pharmacy, and lot number
  • Plain-English research summaries ranked by study quality (peer-reviewed trial vs Reddit anecdote)
  • Drug and supplement interaction checker with severity flags and references
  • One-tap summary PDF to share with prescribing clinician or telehealth visit
Why now

Google Trends shows 2000+ US searches on peptides amid the 'Peptide Wild West' coverage, with consumers hunting for a translator between influencer protocols and actual clinical evidence.

Signals · overall 6/10
Demand
8/10

TIME covers 'droves of biohackers and influencers' using experimental peptides; multiple funded apps (PeptIQ, Protocol, PeptideSchedule, PepedHub) confirm a real and growing consumer market.Why 'Anti-Aging' Peptide Shots Are Trending on Social MediaPeptide-Based Nutrition Trends: 2024 Health Optimization Insights

Whitespace
4/10

PeptIQ already offers dose logging, peptide library, interaction checker, provider-ready FHIR/PDF exports, and a B2B clinic portal — essentially CompoundCompanion's exact feature set. PeptideSchedule and PepedHub ship free interaction checkers.Peptide Tracker App with New Web AccessPeptide Interaction Checker - Peptide Schedule

Monetization
6/10

PeptIQ validates a freemium + Premium subscription and B2B clinic-portal model (per-peptide content, calculators free; advanced analytics, lab integrations, multi-protocol templates gated). Consumer willingness exists but unproven beyond tracker utility.Peptide Tracker App with New Web Access

Longevity
5/10

FDA has issued an 'unprecedented wave' of warning letters against peptide vendors, telehealth platforms, and compounders in 2024-2026, and the BPC-157 ban is already in play — serious existential risk if associated with sourcing. Offsetting this, an FDA panel narrowly voted to ease access to several peptides, leaving the regulatory path genuinely uncertain.The FDA's War on Peptides: A Complete 2024-2026 Enforcement TimelineFDA panel backs unapproved peptide drugs favoured by RFK Jr.

Feasibility
6/10

Dose logging and an 'evidence translator' are straightforward to build, but a credible drug-interaction checker requires curated clinical data with meaningful liability — PeptIQ's 124 cited sources and provider-ready export pipeline show it's doable but not trivial.Peptide Tracker App with New Web Access

peptides · 2000+ searches · USGoogle Trends · 2026-07-27 (today)